All Articles

In front of an enthusiastic audience of nearly 1000 peers and colleagues at the Eighth Annual Navigation & Survivorship Conference, Ms Mulderrig was presented the ONE Award by the Academy of Oncology Nurse & Patient Navigators Cofounder and Program Director Lillie D. Shockney, who articulated the importance of recognizing those in the field exemplifying excellence in oncology nursing.

In today’s healthcare environment, organizations are focusing on quality, outcomes, and evidence-based practice. In this installment of Evidence into Practice, the authors discuss these important qualities in an effective navigation program.

Patient and nurse navigators play an important role in the care of patients from screening through treatment and into survivorship.

In a rural outpatient cancer center affiliated with a nonprofit community hospital, cancer patients prescribed oral chemotherapy receive written and verbal education on the oral chemotherapy agent from the oncology nurse navigator.

The Academy of Oncology Nurse & Patient Navigators and Sarah Cannon, the Cancer Institute of HCA Healthcare, have announced their partnership in a pilot validation study of the 35 AONN+ standardized metrics for navigation programs.

Oncology navigation has made great strides in improving cancer care, including access to quality care, for nearly 3 decades. Navigation programs are well established for most patient populations with solid organ tumors, but less so within the patient populations with liquid cancers. I am pleased to report that this is changing, and it is wonderful to see.

A recent survey of patients with myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia, has identified a strong association between symptom burden and medical disability leave.

Recent advances in the treatment of multiple myeloma have dramatically altered the trajectory of disease, as providers now have several efficacious agents in various drug classes at their disposal.

Despite major and continuing treatment interventions, myeloma remains incurable for most patients, and relapse is an expected part of the disease course. At the National Comprehensive Cancer Network 12th Annual Congress: Hematologic Malignancies, Natalie S. Callander, MD, outlined issues in the management of relapsed/refractory multiple myeloma (RRMM).

Daratumumab (Darzalex), in combination with pomalidomide (Pomalyst) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies, including lenalidomide (Revlimid) and a proteasome inhibitor, was approved by the FDA on June 16, 2017.